Isbn: 9783031671098 - dose finding and beyond in biopharmaceutical development (icsa book series in statistics) (5 resultados)

ISBN
Refinar con la Búsqueda avanzada

Filtrar la búsqueda

  • Libros (5)

  • Nuevo (5)

a

Intervalo de precios personalizado (EUR)

a

    • Idioma: Inglés

      Editorial: Springer, 2024

      3031671090 / 9783031671098

      • Tapa dura

      Librería: AHA-BUCH GmbH, Einbeck, AlemaniaAHA-BUCH GmbH

      Vendedor de 5 estrellas
      Contactar con el vendedor

      Condición: Nuevo

      EUR 326,86

      Envío por EUR 30,50 
      Se envía de Alemania a Estados Unidos de America

      Cantidad disponible: 1 disponibles

      Buch. Condición: Neu. Druck auf Anfrage Neuware - Printed after ordering - This book covers topics in 2 parts: 1) Review of FDA Guidance, 2) Novel Designs and Analyses. While covering basic principles of dose finding, this book details advancements made in drug development.Finding the right dose(s) is one of the most important objectives in new drug development. In Phase I clinical development, one of the objectives is to escalate test doses from low to high. The low doses should be safe, then escalate up to the maximally tolerable dose (MTD). Phase clinical trials then lower test doses to the minimal efficacious dose (MinED). Dose range of a study drug can be thought of as the doses between MinED and MTD. From this dose range, one or a few doses are selected for Phase confirmation. In practice, dose finding is a very difficult in every phase of clinical development for new drugs.The editors brought distinguished researchers and practitioners in biopharmaceuticals and universities, to discuss the statistical procedures, useful methods, and their novel applications in dose finding. The chapters in the book present emerging topics in dose-finding and related interdisciplinary areas. This timely book is a valuable resource to stimulate the development of this growing and exciting field in drug development.

    • Idioma: Inglés

      Editorial: Springer, 2024

      3031671090 / 9783031671098

      • Tapa dura
      • Impresión bajo demanda

      Librería: Brook Bookstore On Demand, Napoli, NA, ItaliaBrook Bookstore On Demand

      Vendedor de 5 estrellas
      Contactar con el vendedor

      Condición: Nuevo

      EUR 182,29

      Envío por EUR 6,80 
      Se envía de Italia a Estados Unidos de America

      Cantidad disponible: Más de 20 disponibles

      Condición: new. Questo è un articolo print on demand.

    • Idioma: Inglés

      Editorial: Springer, Berlin|Springer Nature Switzerland|Springer, 2024

      3031671090 / 9783031671098

      • Tapa dura
      • Impresión bajo demanda

      Librería: moluna, Greven, Alemaniamoluna

      Vendedor de 5 estrellas
      Contactar con el vendedor

      Condición: Nuevo

      EUR 192,60

      Envío por EUR 48,99 
      Se envía de Alemania a Estados Unidos de America

      Cantidad disponible: Más de 20 disponibles

      Condición: New. Dieser Artikel ist ein Print on Demand Artikel und wird nach Ihrer Bestellung fuer Sie gedruckt. This book covers topics in 3 parts: 1) Review of FDA Guidance, 2) Novel Designs and Analyses, and 3) Patient-Centric Drug Development. While covering basic principles of dose finding, this book details advancements made in drug development.Finding.

    • Idioma: Inglés

      Editorial: Springer, Springer Okt 2024, 2024

      3031671090 / 9783031671098

      • Tapa dura
      • Impresión bajo demanda

      Librería: BuchWeltWeit Ludwig Meier e.K., Bergisch Gladbach, AlemaniaBuchWeltWeit Ludwig Meier e.K.

      Vendedor de 5 estrellas
      Contactar con el vendedor

      Condición: Nuevo

      EUR 235,39

      Envío por EUR 23,00 
      Se envía de Alemania a Estados Unidos de America

      Cantidad disponible: 2 disponibles

      Buch. Condición: Neu. This item is printed on demand - it takes 3-4 days longer - Neuware -This book covers topics in 2 parts: 1) Review of FDA Guidance, 2) Novel Designs and Analyses. While covering basic principles of dose finding, this book details advancements made in drug development.Finding the right dose(s) is one of the most important objectives in new drug development. In Phase I clinical development, one of the objectives is to escalate test doses from low to high. The low doses should be safe, then escalate up to the maximally tolerable dose (MTD). Phase clinical trials then lower test doses to the minimal efficacious dose (MinED). Dose range of a study drug can be thought of as the doses between MinED and MTD. From this dose range, one or a few doses are selected for Phase confirmation. In practice, dose finding is a very difficult in every phase of clinical development for new drugs.The editors brought distinguished researchers and practitioners in biopharmaceuticals and universities, to discuss the statistical procedures, useful methods, and their novel applications in dose finding. The chapters in the book present emerging topics in dose-finding and related interdisciplinary areas. This timely book is a valuable resource to stimulate the development of this growing and exciting field in drug development. 272 pp. Englisch.

    • Idioma: Inglés

      Editorial: Springer, Springer Okt 2024, 2024

      3031671090 / 9783031671098

      • Tapa dura
      • Impresión bajo demanda

      Librería: buchversandmimpf2000, Emtmannsberg, BAYE, Alemaniabuchversandmimpf2000

      Vendedor de 5 estrellas
      Contactar con el vendedor

      Condición: Nuevo

      EUR 235,39

      Envío por EUR 60,00 
      Se envía de Alemania a Estados Unidos de America

      Cantidad disponible: 1 disponibles

      Buch. Condición: Neu. This item is printed on demand - Print on Demand Titel. Neuware -This book covers topics in 2 parts: 1) Review of FDA Guidance, 2) Novel Designs and Analyses. While covering basic principles of dose finding, this book details advancements made in drug development.Finding the right dose(s) is one of the most important objectives in new drug development. In Phase I clinical development, one of the objectives is to escalate test doses from low to high. The low doses should be safe, then escalate up to the maximally tolerable dose (MTD). Phase ¿ clinical trials then lower test doses to the minimal efficacious dose (MinED). Dose range of a study drug can be thought of as the doses between MinED and MTD. From this dose range, one or a few doses are selected for Phase ¿ confirmation. In practice, dose finding is a very difficult in every phase of clinical development for new drugs.The editors brought distinguished researchers and practitioners in biopharmaceuticals and universities, to discuss the statistical procedures, useful methods, and their novel applications in dose finding. The chapters in the book present emerging topics in dose-finding and related interdisciplinary areas. This timely book is a valuable resource to stimulate the development of this growing and exciting field in drug development.Springer-Verlag GmbH, Tiergartenstr. 17, 69121 Heidelberg 272 pp. Englisch.